Another phase II trial of margetuximab and pembrolizumab as second-line treatment for HER2-positive gastric cancer (GC) demonstrated notable efficacy, with an objective response rate (ORR) of 28.2%, a disease control rate (DCR) of 63.4%, a median progression-free survival (mPFS) of 4.3 months, and a median overall survival (mOS) of 13.9 months, accompanied by good safety and tolerability (43). Here, ERBB2 is linked to gastric cancer.